Press Releases April 12, 2026 08:00 PM

Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement

Chemed Corporation Secures Five-Year $450 Million Amended Credit Facility with Expansion Option

By Priya Menon CHE
Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement
CHE

Chemed Corporation has entered into an amended and restated five-year revolving credit agreement valued at $450 million, including a $100 million letter of credit component. The agreement features a floating interest rate based on SOFR plus a tiered rate dependent on leverage and includes an expansion option to increase the credit facility by $250 million. Major financial institutions JPMorgan Chase and Bank of America led the arrangement. Chemed operates through its subsidiaries VITAS Healthcare and Roto-Rooter, serving hospice care and plumbing services sectors respectively.

Key Points

  • Chemed secured a $450 million revolving credit facility with a five-year term and $100 million designated for letters of credit.
  • The credit agreement's interest rate is based on the secured overnight financing rate (SOFR) plus a tiered spread determined by the company's leverage ratio.
  • An expansion feature allows Chemed to increase the credit revolver by an additional $250 million, providing financial flexibility.

CINCINNATI, April 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation ("Chemed") (NYSE:CHE) announced that it has entered into an Amended and Restated Credit Agreement for its Credit Facility (“Credit Agreement”). JPMorgan Chase Bank, N.A., acted as the Administrative Agent, Joint Lead Arranger and Joint Bookrunner for this transaction. Bank of America, N.A., was Joint Lead Arranger, Joint Bookrunner and Syndication Agent and PNC N.A. and U.S. Bank N.A. were Co-Documentation Agents.

Terms of the Credit Agreement consist of a five-year $450 million revolving credit facility including $100 million for letters of credit. The interest rate on this Credit Agreement has a floating rate that is generally the secured overnight financing rate (“SOFR”) plus an additional tiered rate which varies based on our current leverage ratio. The Credit Agreement includes an expansion feature that provides Chemed the opportunity to increase its revolver by an additional $250 million.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT:Michael D. Witzeman  (513) 762-6714



Risks

  • The floating interest rate tied to SOFR could increase financing costs if market rates rise, impacting operating expenses.
  • The company's leverage levels influence the interest margin, so increased leverage could raise borrowing costs, affecting financial stability.
  • Forward-looking statements caution risks related to future performance and market uncertainties that could impact the company's financial health.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026